Nkarta Inc. (NKTX) News
Filter NKTX News Items
NKTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NKTX News Highlights
- For NKTX, its 30 day story count is now at 2.
- Over the past 2 days, the trend for NKTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- ASH, DEC and SHEL are the most mentioned tickers in articles about NKTX.
Latest NKTX News From Around the Web
Below are the latest news stories about NKARTA INC that investors may wish to consider to help them evaluate NKTX as an investment opportunity.
Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & ExpositionSOUTH SAN FRANCISCO, Calif., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced a poster presentation at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition featuring follow-up data from its Phase 1 clinical trial that evaluates NKX101 in patients with relapsed or refractory acute myeloid leukemia (r/r AML). NKX101 is an allogeneic, off-the-shel |
All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to BuyNkarta, Inc. (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
T. Rowe Price Investment Management, Inc. Reduces Stake in Nkarta IncT. Rowe Price Investment Management, Inc. (Trades, Portfolio), a renowned investment firm, has recently adjusted its investment in Nkarta Inc (NASDAQ:NKTX), a biopharmaceutical company. This transaction had a minor impact of -0.01% on the firm's portfolio, with the shares being traded at a price of $2.03. Post-trade, T. Rowe Price Investment Management, Inc. (Trades, Portfolio) holds 430,350 shares of Nkarta Inc, which constitutes a 0.80% stake in the company. |
Nkarta Reports Third Quarter 2023 Financial Results and Corporate HighlightsFDA clearance of IND for NKX019 in lupus nephritis expands pipeline into autoimmune diseaseNKX019, a first-in-class engineered NK cell therapy, has disease-modifying potential in autoimmune disease while maintaining NK-driven safety profileNew pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapyPartnership with Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, to support |
These Biotech Stocks Could Double Your Money, According To AnalystsThe biotech industry has been in the limelight since the COVID-19 pandemic, with public and private sectors pouring in funds to bolster innovation and the development of relevant drugs. Approximately 63% of public biotech firms reported revenue growth in 2021. Emerging biotech companies, which have annual revenue below $500 million, recorded a median 40% annual revenue growth rate, outpacing industry giants, which reported a lower 35% average annual revenue growth rate. While the pandemic-relate |
Nkarta to Participate at Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation at two upcoming investor conferences: Stifel Healthcare ConferenceNovember 14, 202310:55 a.m. ET – fireside chat Evercore ISI HealthCONx ConferenceNovember 28, 202312:30 p.m. ET – fireside chat A simultaneous webcast of each event will be available on the Investors section of Nkarta’s we |
Want To Invest In Penny Stocks? Here Are Three That Analysts Think Could Deliver Over 300% ReturnsPenny stocks are risky but have the potential to triple initial investments. While risk-averse investors might associate penny stocks with gambling, conducting proper research and noting market sentiment regarding such low-value stocks can help traders identify strategic investment opportunities. But pump-and-dump schemes where market-makers artificially inflate the price of penny stocks through advertising are fairly common. While the promoters often end up cold calling clients or sending email |
Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus DrugNkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidate, NKX019, for the treatment of lupus nephritis. |
'The world increasingly needs Arm,' says KeyBanc: 4 big analyst picksHere is your Pro Recap of the biggest analyst picks you may have missed since yesterday: a buy initiation at Arm Holdings, and upgrades at Nkarta, Elastic , and Hudson Pacific Properties. KeyBanc began coverage on Arm Holdings (NASDAQ:ARM) with an Overweight rating and a price target of $65.00, as reported in real time on InvestingPro. The initiation is the latest of many buy-equivalent ratings stamped on the chipmaker after its IPO last month, with a raft of brokerages starting coverage last week - including BofA Securities, TD Cowen, Goldman Sachs, and Citi - and most of them assigning buy-equivalent ratings. |
Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus NephritisLupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a partnership with Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing the engineered natural killer (NK) cell therapy NKX019 for refractory lupus nephritis that has not responded to standard treatment. Lupus Therapeutics has provided advisory services and will support Nkarta in early development through select sites of the Lupus Clinical Investigators Network (LuCIN) comprised of |